Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

Abstract

There is a need for novel therapies targeting hypoxic cells in tumors. These cells are associated with tumor resistance to therapy and express hypoxia inducible factor-1 (HIF-1), a transcription factor that mediates metabolic adaptation to hypoxia and activates tumor angiogenesis. We previously developed an oncolytic adenovirus (HYPR-Ad) for the specific… (More)
DOI: 10.1158/0008-5472.CAN-06-3244

Topics

7 Figures and Tables

Cite this paper

@article{Post2007TargetedCG, title={Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.}, author={Dawn E. Post and Eric M. Sandberg and Michele M Kyle and N. Devi and Daniel J. Brat and Zhiheng Xu and Mourad Tighiouart and Erwin G Van Meir}, journal={Cancer research}, year={2007}, volume={67 14}, pages={6872-81} }